These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 14531907)

  • 1. Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications.
    Saeki Y; Mima T; Ishii T; Ogata A; Kobayashi H; Ohshima S; Ishida T; Tabunoki Y; Kitayama H; Mizuki M; Katada Y; Asaoku H; Kitano M; Nishimoto N; Yoshizaki K; Maeda M; Kon S; Kinoshita N; Uede T; Kawase I
    Br J Haematol; 2003 Oct; 123(2):263-70. PubMed ID: 14531907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.
    Standal T; Hjorth-Hansen H; Rasmussen T; Dahl IM; Lenhoff S; Brenne AT; Seidel C; Baykov V; Waage A; Børset M; Sundan A; Hjertner O
    Haematologica; 2004 Feb; 89(2):174-82. PubMed ID: 15003892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Contribution to the evaluation of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and in individual clinical stages of multiple myeloma].
    Scudla V; Petrová P; Minarík J; Pika T; Budíková M; Bacovský J; Repovský S
    Vnitr Lek; 2010 Jun; 56(6):591-601. PubMed ID: 20681472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients.
    Colla S; Morandi F; Lazzaretti M; Rizzato R; Lunghi P; Bonomini S; Mancini C; Pedrazzoni M; Crugnola M; Rizzoli V; Giuliani N
    Leukemia; 2005 Dec; 19(12):2166-76. PubMed ID: 16208410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.
    Babarović E; Valković T; Budisavljević I; Balen I; Štifter S; Duletić-Načinović A; Lučin K; Jonjić N
    Pathol Res Pract; 2016 Jun; 212(6):509-16. PubMed ID: 26997492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma.
    Steiner N; Hajek R; Sevcikova S; Borjan B; Untergasser G; Göbel G; Gunsilius E
    Anticancer Res; 2018 Sep; 38(9):5087-5092. PubMed ID: 30194153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of bone sialoprotein, osteopontin, and β2-microglobulin in stage I of multiple myeloma.
    Maaroufi A; Khadem-Ansari MH; Khalkhali HR; Rasmi Y
    J Cancer Res Ther; 2020; 16(1):98-101. PubMed ID: 32362616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model.
    Caers J; Günthert U; De Raeve H; Van Valckenborgh E; Menu E; Van Riet I; Van Camp B; Vanderkerken K
    Br J Haematol; 2006 Feb; 132(4):469-77. PubMed ID: 16412019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of hepatocyte growth factor, syndecan-1, and osteopontin in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Minarik J; Pika T; Bacovsky J; Petrova P; Langova K; Scudla V
    ScientificWorldJournal; 2012; 2012():356128. PubMed ID: 22629140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and different stages of multiple myeloma.
    Scudla V; Petrova P; Minarik J; Pika T; Bacovsky J
    Neoplasma; 2011; 58(6):499-506. PubMed ID: 21895403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas.
    Le QT; Sutphin PD; Raychaudhuri S; Yu SC; Terris DJ; Lin HS; Lum B; Pinto HA; Koong AC; Giaccia AJ
    Clin Cancer Res; 2003 Jan; 9(1):59-67. PubMed ID: 12538452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical significance of serum osteopontin in patients with multiple myeloma].
    Kang SY; Lee JJ; Lee WI
    Korean J Lab Med; 2007 Dec; 27(6):400-5. PubMed ID: 18160829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of serum levels of Dickkopf-1 (DKK-1) in monoclonal gammopathy of undetermined significance and multiple myeloma].
    Ščudla V; Petrová P; Pika T; Lochman P; Minařík J; Bačovský J; Srovnalík K
    Cas Lek Cesk; 2015; 154(4):181-8. PubMed ID: 26357861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells.
    Mylin AK; Rasmussen T; Johansen JS; Knudsen LM; Nørgaard PH; Lenhoff S; Dahl IM; Johnsen HE;
    Eur J Haematol; 2006 Nov; 77(5):416-24. PubMed ID: 16930142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy.
    Miguel-Garcia A; Matutes E; Tarin F; Garcia-Talavera J; Miguel-Sosa A; Carbonell F; Catovsky D
    J Clin Pathol; 1995 Sep; 48(9):835-9. PubMed ID: 7490317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteopontin dysregulation and lytic bone lesions in multiple myeloma.
    Robbiani DF; Colon K; Ely S; Ely S; Chesi M; Bergsagel PL
    Hematol Oncol; 2007 Mar; 25(1):16-20. PubMed ID: 17044113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of the bone marrow plasma cell cytoplasmic light chain ratio in differentiating between multiple myeloma and monoclonal gammopathy of undetermined significance.
    Majumdar G; Grace RJ; Singh AK; Slater NG
    Leuk Lymphoma; 1992 Dec; 8(6):491-3. PubMed ID: 1297481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
    Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD
    Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-6 in multiple myeloma: correlation with disease activity and Ki-67 proliferation index.
    Thaler J; Fechner F; Herold M; Huber H
    Leuk Lymphoma; 1994 Jan; 12(3-4):265-71. PubMed ID: 8167557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.